In a surprising twist, Neximmune Inc (NEXI) has shown an exceptional performance during the pre-market hours today, creating ripples in the financial realm. The stock experienced a remarkable surge of 208.21%, or $4.95 in this early trading session. Notably, the trading volume in the pre-market soared to a substantial 8.31 million shares, signaling a surge in investor engagement and increased market dynamics.
The substantial shift in Neximmune’s pre-market activity sparks curiosity, prompting a closer look at the underlying factors behind this impressive stock value change. Market participants are closely monitoring the consequences of this significant pre-market upswing as the trading day unfolds.
On October 24, 2023, NexImmune, Inc. (Nasdaq: NEXI) disclosed the expansion of the collaborative research initiative involving NexImmune, Yale, and JDRF, aimed at exploring the application of NexImmune’s AIM nanoparticles in conjunction with an anti-CD3 mAb to tolerize, deplete, or modulating diabetes antigen-specific T cells.
As part of the extension, JDRF has allocated an additional grant of $300,000 to Yale under its Cures research portfolio, focusing on therapies for type 1 diabetes (T1D) prevention.
The JDRF grant will continue supporting investigations into using NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab, known to modulate the pathogenic immune response acutely.
The integration of anti-CD3 treatment with NexImmune’s injectable therapy presents an opportunity to specifically target and modulate T1D antigen-specific T cells, potentially sustaining their non-responsiveness to extend benefits and induce tolerance. The unique properties of NexImmune’s nanoparticles offer the potential to further amplify the impact of anti-CD3 by influencing the residual T1D-specific T cells.